Organon India LimitedMumbai, Maharashtra
Products and Services
- Pneumovax 23
- Diplene AF
- Naturolax And Naturolax Forte
- Quadriderm RF
Organon India Limited was established in the year 1963 at Mumbai. Our team of quality controllers tests these products on numerous parameters to ascertain their quality. Also, our range is formulated in compliance with international quality... read more
About UsToday's MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Merck offers a diversified portfolio of prescription medicines, vaccines and animal and consumer health products. This portfolio is complemented by a robust pipeline with more than 15 promising late-stage candidates spanning critical therapeutic categories. Merck now has approximately 106,000 employees and operates in more than 140 countries around the world. Merck anticipates sales from emerging markets to make up more than 25 percent of its global sales by 2013. The company takes advantage of the combined strengths of Merck and Schering-Plough to create a more customer-focused, innovative, and diversified global health care company positioned to capitalize on the company's greatest opportunities for growth, particularly in emerging markets, biologics and vaccines. Merck has five primary divisions: Global Human Health, Animal Health, Consumer Health Care, Merck Research Laboratories and Merck Manufacturing. MSD in India MSD operates its human health business in India through three separate legal entities: MSD Pharmaceuticals Private Limited, Organon (India) Private Limited, and Fulford (India) Limited. Since its existence in India, the company has moved quickly in laying the foundation for a business that is differentiated by its focus through launching innovative products relevant to India. KEY THERAPEUTIC AREAS MSD in India currently operates in various therapeutic areas in human health, including Metabolics, Cardiovascular, Vaccines, Critical Care, Immunology, Virology, Oncology, Women's Health, Dermatology, Respiratory, Musculoskeletal and Primary Care, and offers a strong and diversified product portfolio of over 75 brands in total. Commitment to India MSD has a long term commitment to India both in terms of bringing best in class products and also making necessary investments to serve the Indian patients. MSD will continue in its endeavor to help shape the healthcare paradigms in India through initiatives like responsible pricing, integrated disease management programs; partnerships for research & access; capacity building initiatives, amongst others. In addition to setting up a sales and marketing structure to market best in class products in India, MSD is also coordinating research projects with clinical investigators in India's leading hospitals and universities, for development of new drugs to address unmet medical needs for Indian patients. Partnerships MSD has a number of collaborative partnerships in India in line with our stated aim of developing innovative, first-in-class products that change basic medical practice, improve health and save lives. Some of the key partnerships include: Partnership between MSD in India and Sun Pharmaceutical Industries Ltd. (Sun Pharma) for co-marketing MSD's diabetes drugs sitagliptin and sitagliptin plus metformin in India. Partnership with Orchid Pharma (Orchid Chemicals and Pharmaceuticals Ltd.) to identify and develop novel anti-bacterial and anti-fungal drug candidates. Partnership between MSD and Wellcome Trust U.K. to form MSD Wellcome Trust Hilleman Laboratories, a first of its kind joint venture to develop affordable vaccines for low income countries. The India-based ‘Hilleman Laboratories’ operates on a Not-for-Profit Basis to focus on developing affordable vaccines to prevent diseases that commonly affect low-income countries.
Our TeamMr. K.G. Ananthakrishnan
Managing Director Mr. K.G. Ananthakrishnan is Managing Director of MSD in India. In this capacity, KG (as he is widely known), leads all three legacy entities in India: Fulford (India) Limited, Organon India Pvt. Ltd. and MSD Pharmaceuticals Pvt. Ltd. KG is responsible for South Asia Region operation which includes Sri Lanka, Bangladesh, Pakistan and India. KG started his industry career in 1976 with Novartis (and its former companies) as a medical representative, eventually progressing to the position of Head, Sales & Marketing for one of its Business Units. He then moved on to senior management positions in Pharmacia India, Pfizer and Schering-Plough. KG holds a Masters in Marketing Management from Jamnalal Bajaj Institute of Management Studies, Bombay University, India and a Bachelor of Science degree from Osmania University, Hyderabad, India. He has done a program on Finance from Insead, France and a Senior Management Program at the Wharton Business School, U.S.
KG has been a speaker in leading Management schools including Columbia University – U.S, Indian Institute of Management, Indore, Indian School of Business (ISB) and Narsee Monjee Institute of Management Studies. KG is actively involved in industry related matters and is an active member of OPPI’s Executive Committee. Mr. Vivek V. Kamath
Sr. Director – Cardio Vascular, Metabolics, Market Access & Public Market Mr. Vivek V. Kamath is the Sr. Director – Cardio Vascular, Metabolics, Market Access & Public Market, he joined MSD in India in July 2012. He has over 24 years of experience in Marketing, Sales and General Management in India, ASEAN & South Asia with healthcare organizations such as Wockhardt, Fulford, Warner Lambert, Pfizer, Ranbaxy, Novartis and Roche. He has led business teams and managed portfolios in Prescription, Over-the-counter (OTC) & Diagnostics segments, partnering with healthcare professionals, consumers, diverse trade channels & Government/ Non-Government healthcare entities.
Mr. Kamath holds a Masters in Marketing Management and Bachelor's degree in Microbiology from the University of Mumbai, India.
Ms. Annapurna Das
Director – Neighboring Markets & India Vaccines Business Ms. Annapurna Das joined Fulford in January 2007 as Associate Director - Strategy & Business Development. She is currently working as the Director - Neighboring Markets and Vaccines Business for MSD in India. She has a rich experience of 17 years in leadership roles for all strategic planning and organisation building within the sales and marketing as well as business development functions of various healthcare companies.
Ms. Das is an MBA from Madurai Kamaraj University and holds a B. Tech. degree from Birsa Institute of Technology (BIT), Sindri. Mr. Sameer Tamhane
Sr. Director - Human Resources Mr. Sameer Tamhane joined the organization in February 2004. He has more than 27 years of comprehensive experience in Human Resource (HR), Employee Relations (ER) and Administration in domains such as consumer durable (Godrej-GE), IT (Silverline and Blue Star Software), industrial products (Owens Corning), mutual funds (Reliance) and pharma (Aventis). He was visiting faculty for HR subjects at various post graduate management institutes in Mumbai. He is also Governing Board member of Indian Education Society. He won WILL Award for gender diversity in 2014.
Mr. Tamhane holds a Bachelor degree in Mechanical Engineering and a Master’s degree in Management Studies (MBA) in Human Resources Management from Mumbai University. Dr. Swashraya Shah
Sr. Director - Medical Affairs & Innovation leader for MSD in India
- Year of Establishment
- Nature of Business
- Number of Employees
101 to 500 People
Send your enquiry to this supplier
Contact DetailsOrganon India LimitedSreeraj Roy+91-22-56661724
Nishuvi, 1st Floor, 75, Dr. A. B. Road, Worli
Mumbai - 400 018
Mumbai - 400 018